|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Star_Trek:_Deep_Space_Nine:_The_Siege_of_AR-558
gptkb:The_Siege_of_AR-558
|
|
gptkbp:activities
|
inhibitor of the m TOR pathway
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
|
|
gptkbp:collaborations
|
gptkb:healthcare_organization
|
|
gptkbp:developed_by
|
gptkb:Ariad_Pharmaceuticals
|
|
gptkbp:dosage_form
|
varies by trial
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
gptkbp:frequency
|
daily
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AR-558
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_tested_for
|
clinical trials
|
|
gptkbp:manager
|
oral
|
|
gptkbp:market
|
not approved for market
|
|
gptkbp:related_to
|
other m TOR inhibitors
|
|
gptkbp:research_areas
|
gptkb:Massachusetts_Institute_of_Technology
|
|
gptkbp:research_focus
|
oncology
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
|
|
gptkbp:social_structure
|
gptkb:Cloud_Computing_Service
|
|
gptkbp:status
|
investigational
|
|
gptkbp:target_audience
|
patients with solid tumors
|
|
gptkbp:targets
|
gptkb:healthcare_organization
|
|
gptkbp:year_created
|
gptkb:2010
|